Study of the efficacy and safety of hexapeptide succinate in hospitalized patients with community-acquired pneumonia: a single-blind, multicenter, randomized, comparative, placebo-controlled study
Authors:
- S. N. AvdeevSAS. N. Avdeev
- L. A. BalykovaLBL. A. Balykova
- T. I. ChudinovskikhTCT. I. Chudinovskikh
- N. E. KostinaNKN. E. Kostina
- N. M. SeleznevaNSN. M. Selezneva
- R. S. KozlovR. S. Kozlov
- I. V. GostevaIGI. V. Gosteva
- A. V. TaganovATA. V. Taganov
- N. Yu. PshenichcnayaNPN. Yu. Pshenichcnaya
- O. A. AchverdovaOAO. A. Achverdova
- K. N. KoryanovaKKK. N. Koryanova
- 14 December 2025
- journal article
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (6)
Abstract
The search for treatment methods for community-acquired pneumonia (CAP) is currently urgent. Therefore, the search for new therapeutic solutions, including the use of innovative drugs with pronounced anti-inflammatory, antioxidant, and regenerative properties that help prevent lung damage and minimize complications when used as part of combination therapy, is in high demand. The aim of the study was to evaluate the efficacy and safety of tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate (Ambervin® Pulmo (AP), Promomed Rus LLC, Russia) in hospitalized patients with CAP. Methods. The study included 208 patients hospitalized with CAP and randomized into 2 groups. Along with standard therapy, patients in group 1 (n = 104) received tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate by inhalation for 10 days at a dose of 11.6 mg once daily; group 2 (n = 104) received placebo by inhalation once daily. The prescribed therapy was assessed according to primary and secondary efficacy and safety endpoints. Results. Clinical cure by Visit 5 (day 10) was observed in 57 (54.81%) of 104 patients receiving AP (Group 1) and in 35 (36.08%) of 97 patients in the placebo group. The mean time (± SD, per day) to achieving the criteria of clinical stability or discharge from the hospital was 2.54 ± 0.89 days in the AP group and 3.38 ± 1.64 days in the placebo group. Statistically significant advantages of AP over placebo in other secondary endpoints also indicate the high efficacy of the therapy. The analysis demonstrated a favorable safety profile of the study drug. No new data on the safety of AP that would affect the change in its safety profile were identified. Conclusion. In patients receiving tyrosyl-D-alanylglycyl-phenylalanyl-leucyl-arginine succinate, compared to the placebo group, body temperature normalized as early as the third day of therapy, and the symptoms improved, including cough, sputum production, headache, weakness, night sweats, and chills. The use of AP was associated with reduced need for antibacterial medications and lower risk of developing complications of CAP. The results of the clinical trial demonstrated the clinical efficacy and pharmacoeconomic feasibility of hexapeptide succinate therapy.Keywords
This publication has 17 references indexed in Scilit:
- Community-acquired pneumoniaThe Lancet, 2025
- Atypical pathogen community-acquired pneumonia: an analysis of clinical characteristics, drug treatment, and prognosis in the related patientsMolecular Biology Reports, 2025
- Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature reviewExpert Review of Vaccines, 2023
- Synthetic Analogue of Leu-Enkephalin in COVID-19 (a Prospective Clinical Study)General Reanimatology, 2022
- Clinical prognostic significance of serum high mobility group box-1 protein in patients with community-acquired pneumoniaJournal of International Medical Research, 2019
- Scored minor criteria for severe community-acquired pneumonia predicted betterRespiratory Research, 2019
- Radiologic Diagnosis and Hospitalization among Children with Severe Community Acquired Pneumonia: A Prospective Cohort StudyBioMed Research International, 2019
- Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trialsDiagnostic Microbiology and Infectious Disease, 2013
- SUCCINIC ACID DERIVATIVES IN THERAPY FOR CEREBROVASCULAR DISEASENeurology, Neuropsychiatry, Psychosomatics, 2010
- The enkephalinsThe Science of Nature, 1978